

September 13, 2021

BSE LimitedNational Stock Exchange of India LimitedP. J. TowersExchange PlazaDalal Street,Bandra Kurla ComplexMumbai - 400 001Bandra (E),Mumbai - 400 051

Dear Sirs,

Sub.: Intimation of Investor/ Analyst Meetings

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be meeting the following Institutional Investors as per below schedule. The schedule may undergo change due to exigencies on the part of Investors/ Analysts/Company.

Date	Investors Name
14-Sep-21	New Vernon
14-Sep-21	White Oak
16-Sep-21	Old Bridge
17-Sep-21	Motilal MF

We also enclose the presentation to be used during our interaction.

This is for your information and record.

Thanking you,

Yours faithfully, For Jubilant Ingrevia Limited

Deepanjali Gulati Company Secretary

Encl.: as above


A Jubilant Bhartia Company



Jubilant Ingrevia Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel: +91 120 4361000 Fax: +91 120 4234895-96 www.jubilantingrevia.com Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223 Uttar Pradesh, India CIN : L24299UP2019PLC122657



Investor Presentation September'21



Disclaimer



Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Effective 1st February 2021, Life Science Ingredients business of Jubilant Pharmova Limited (earlier Jubilant Life Sciences Limited) demerged to Jubilant Ingrevia Limited and post demerger the consolidated financial results of the Jubilant Ingrevia Limited for the quarter and the year ended 31 March 2021 comprised results only for two months of operations, starting from 1st February 2021.

To provide the comprehensive picture of the operations of the Company on continuing basis the results for previous periods has been presented on Pro-forma basis by using relevant portion of the published results of LSI Segment - Jubilant Pharmova Limited on Pro-forma basis as Under :

- Results Q1'FY21 has been derived on Pro-forma basis from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited.
- As explained in the Financial Results presentation deck for Q'4 FY 21 we had earlier presented results for fully year FY 21 on Pro-forma basis by combining the results from 01 April 2020 to 31 January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited and results for Q4'FY21 on Pro-forma basis by combining the results for January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited
 - EPS for previous periods has been computed assuming existence of share capital throughout the period

NOTES:

- 1. The numbers for the quarter have been reclassified and regrouped wherever necessary
- 2. Closing Exchange Rate for USD 1 at Rs 73.11 as on March 31, 2021 and Rs 74.33 as on June 30, 2021

Jubilant Bhartia Group - Snapshot



Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India





Strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services and Therapeutics, Performance Polymers, Food Service (QSR), Auto, Consulting in Aerospace and Oilfield Services




Global presence through investments in India, USA, Canada, Europe, Singapore, China, Sri Lanka and Bangladesh



Employs around 46,000 people across the globe with Over 2,400 in North America


Jubilant Ingrevia: Glorious Four Decades of Growth





Business Segments & Integrated Operations





Executive Leadership Team





Rajesh Srivastava Chief Executive Officer & Managing Director 34 years of industry experience



Anil Khubchandani

President -Speciality Chemicals 29 years of industry experience



R Kumar President – Nutrition & Health Solutions 35 years of industry experience



Chandan Singh President – Life Science Chemicals 35 years of industry experience



Prakash Bisht President & **Chief Financial Officer** 32 years of industry experience



Anant Pande President & Chief of Operations 35 years of industry experience



Vinita Koul SVP & Head- HR 25 years of industry experience




Prasad Joglekar EVP & Head -Supply Chain 28 years of industry experience

Leadership team has an average 30 years of industry experience

Jubilant Ingrevia: Company Snapshot





Source: M&M Report 2020


Strong Presence in Industry Value Chain



	<i>(</i>				and a state of the
<		CDMO Services			Commercial Scale
	Discovery Process De	evelopment Clini	ical Phase Manufacturi Phase I / II / III	ing Intermed Custom Man	
Pharma	 Route Design, Pro- familiarization & C Analytical Develo Evaluation 	Deptimization therapeution pment & Safety • Phase II: 3	Intermediates for Anti-Vira c, Cosmetic Applications Intermediates for Antineop iral, Antithrombotic therape	plastic,	Jubilant Ingrevia' s Presence
Value Chain		<u></u>	Intermediates /	Custom Manufacturing	
	Feedstock	Speciality Buildin	- /	Speciality Chemicals	(n-1/n-2) GMP Intermediates
	•Ethanol	 Acetic Anhydride Propionic Pryridine Anhydride Ethyl Acetate Cyano Press 	& •Lutidines •Halogena	s & Collidines ated Derivatives ridine based derivatives	 •2-Hydroxy-5-Methyl Pyridine •Diethyl-3-Pyridinyl Borane •DB-3 •PNB (7,10-Dichloro-2and more under NDA methoxybenzo(b)-1,5-naphthyridine)
	Development		Intermediates		Pesticide Technical/ Pesticide
	Stage I / II / III			Speciality Chemicals	Active Ingredient Formulation
Agro Value Chain	 Stage III: 1 Intermediate for Insecticide application Stage II: 3 Intermediates for Insecticide & Fungicide Applications 	•Acetic Anhydride •Propionic Anhydride •Acetaldehyde	 Pyridine & Picolines Cyano Pyridines 	 Amino Pyridines Alkyl Derivatives Halogenated Derivatives Other Pyridine derivatives Speciality Ethanol 	
	Raw Materials	Health Ingredients	Formulations / Prei	mixes Performance l	ngredients End-Products
Nutrition Value Chain	 Cyano Pyridines Acetic Anhydride Ethyl Acetate Inosito 	n B3 (Niacinamide & Niacin) n B4 (Choline Chloride) avin Phosphate Sodium ol Hexa Nicotinate ates (Chromium & Zinc)	 AD2 Premix for Fortifica ACE Premix for Beverag Gut Health solution Amino acids Egg quality enhancers and other 18+ branded p 	es •Acidifier •Soy Lecithin •Aspartame •Citric Acid, Maleic A	

Industry Overview: Presence in Large & Growing Markets





Source: M & M Report 2020 Conversion Factor from INR to Dollar: INR 73.11/Dollar


3) Merchant Market



BUSINESS SEGMENTS


Speciality Chemicals – Segment Snapshot






Nutrition & Health Solutions – Segment Snapshot





Life Sciences Chemicals – Segment Snapshot





Multi Location Manufacturing & Operation Excellence



Manufacturing Facilities



Gajraula, Uttar Pradesh, India

Integrated facility for Speciality Chemicals & Life Science Chemicals



Bharuch, Gujarat, India Speciality Chemicals, Nutrition & Health Ingredients & Life Science Chemicals facility located in SEZ

International offices in US, Europe, Japan & China



Nira, Maharashtra, India Life Science Chemicals



Samlaya, Gujarat, India Animal Nutrition & Health Solutions



Ambernath, Maharashtra, India Speciality Chemicals



RC 14001:2015 Gajraula, Bharuch & HO Noida

We operate 50 Plants across 5 sites in 3 states

Operation Highlights Health & Safety: Multi-Chemistry, Ecologically World Class GMP cGMP compliant **In-house Utilities** benchmarking global Multi-Product and **Harmonized Practices** facility at Bharuch **Pilot Plant** performance by **Process Condition** Chilworth Dekra- FY'07 & handling expertise Temp, Humidity & **Captive Power Plant** 20 – 1000L Reactors Incinerators, ETPs, Chola MS- FY'21 **Differential Pressure** (Gajraula), Own Steam Multi Effect (Glass Assemblies. Controlled Areas with Cryogenic & Plug Flow Generating Boilers, **Evaporators**, Reverse Compliance: 3,800+ Large capacities in ISO-8 (Class 100,000) **Chilled Water & Brine** Osmosis, Water reactors, Lyophilizer compliance items **Continuous & Batch** Clean rooms Unit Autoclaves **Polishing Plants** through 'EY' processes **Conformity tool**


Jubilant Ingrevia: Global Accreditation



Select Certifications		Gajraula	Bharuch	Nira	Samlaya	Ambernath
No. of	plants	36	5	13	5	2
Responsible Care*	Responsible Care RC 14001:2015	\checkmark	\checkmark			
150 9001:2015	ISO 9001:2015	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
22000-2005	ISO 22000:2005	\checkmark	\checkmark	\checkmark		
	ISO 14001:2015	\checkmark	\checkmark	\checkmark	\checkmark	
45001:2018	ISO 45001:2018	\checkmark	\checkmark		\checkmark	
<u>Jssai</u>	FSSAI	\checkmark	\checkmark	\checkmark	\checkmark	
FAMos	FAMI-QS		\checkmark		\checkmark	
KOSTIER	HALAL KOSHER	\checkmark	\checkmark	\checkmark		
A Manufacity	GMP	\checkmark	\checkmark			
Ouality Bulling	Certification	State FDA GMP	State FDA GMP & WHO GMP			
TOGETHER FOR SUSTAINABILITY	TFS Audit		✓ (FY'19)	✓ (FY'20)		
ecovadis	Certification f	or Jubilant Life Scie	nces Ltd.: FY'20 (Gold Cat	egory)		

Business Excellence and Digital Transformation





Research Development & Technology (RDT)





3 RDT centers in Noida, Gajraula and Bharuch to Gr

90 highly qualified scientists (~20 PhDs)

35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Grignard etc.

> 65 New Products Pipeline for next 5 years

	1000s MT			100s MT	MTs		
Key	Aromatization	Oxidation	Sandmeyer	Grignard	Fluorination	Hoffmann	Bu-Li
Technology	Vapour Phase Reactions	Ammoxidation,	Bromination	Methylation	Thiol Handling	Re-arrangement Methoxylation	Reaction Iodination
Platforms	Chlorination /	Fermentation	Esterification	Quarternisation	Ethylene Oxide Reaction	N-Formylation	Chiral Synthesis
	Photochlorination	Ketene Technology	Hydrogenation	Chichibabin		De-alk	ormylation
	→ Optim	ization Existi	ng product's proce	esses to remain gl	obally competitiv	'e	
	— Ехра	nsion Focus	on Agro, Nutritio	oduct Development			
Key focus areas for RDT	Academic C	ollaboration New t	echnologies by ac	ademia collabora	tion /expanding ir	nternal infrastructu	ure
		Advisory ard	Strong Scientific advisory board to support RDT				
	Centre of	Excellence For Bio	o catalysis, Flow ch	nemistry, Chemo c	atalysis, Gas phas	e Catalytic Chemis	stry

CSR - Jubilant Bhartia Foundation



Established in 2007

Mission: To develop multi-stakeholder sustainable models to bring about 'social change' involving knowledge generation & sharing, experiential learning & entrepreneurial ecosystem





*A sister organization of World Economic Forum in Partnership with Jubilant Bhartia Foundation

Education




- 50,000 students in 275 govt. primary schools
- Developed digital platform "Jubilant Education System"
- Introduced Digital **Classes** in Government schools

Improving Health

- Jubilant Aarogya -Affordable healthcare services
- Swasthya Prahari **Conduction Growth** Monitoring of **10,000+** children from 0 to 5 yrs of age and BCC to decrease malnutrition

Escalating



- Skill Development program for training 2500 youth every year.
- Promote Self sustainable **Micro Enterprise**

Entrepreneurship

Social



- JBF with the Schwab Foundation recognize & award exceptional individuals in Social **Business**
- Providing business to social enterprises

FACE- Centre for Excellence




An initiative between **CII &** Jubilant Bhartia to improve productivity of agriculture and increase farmer income



Sustainability Journey





> **37%** Reduction in Specific Water Consumption wrt FY 13

- **3 out of 5** sites are Zero Liquid Discharge
- **27%** Reduction in Specific Greenhouse Gas Emissions wrt FY 13
- **25%** Reduction in Specific Energy Consumption wrt FY 13
- **44964** Training man-days were imparted from FY 14
- **870 families** supported by providing sustainable livelihood
- > 20 schools Digitization completed
- > **1,70,000** Trees planted

C Rating

2020

CLIMATE





For more detail visit our Sustainability page https://jubilantingrevia.com/aboutus/sustainability **Responsible Care**

Our sustainability goals Alignment with **UN Sustainable Development Goals (SDGs)**



#JubilantCares | Stronger Together | Our Efforts during Pandemic



Oxygen Support during Crisis



Provided **oxygen cylinders** & concentrators at doorsteps of employees in need & installed Oxygen plant.



Ambulances &

Provided Assistance in arranging ambulances and hospital beds for employees and their families

Isolation Centers



Company aided isolation centers at Noida, Mumbai, Indore & Chennai with medical assistance

Vaccination Drive



Massive Vaccination drive across India for all our employees & their families

RTPCR Testing Camps



Organized RTPCR Testing camps at our corporate offices & site offices

Yoga & Wellness



Appointed Yoga & wellness experts to help our employees deal stress during these tough times



Launched Employee Well-Being and **Assistance Program**

Doctors On Call



24*7 Doctor On Call facility for all employees

Financial Support



Put together a strong ex-gratia financial package to support the families of our deceased employees




Financials

Jubilant Ingrevia – Q1'FY22 Financial Highlights



Particulars ¹	Q1'FY21 ²	Q1'FY22	YoY (%)
Revenue			
Speciality Chemicals	257	305	18%
Nutrition & Health Solutions	148	167	13%
Life Science Chemicals	331	673	103%
Total Revenue from Operations	737	1,145	55%
Reported EBITDA	127	287	126%
Speciality Chemicals	69	84	22%
Nutrition & Health Solutions	31	27	(15%)
Life Science Chemicals	24	184	677%
Unallocated Corporate (Expenses)/Income	3	-7	-
РАТ	53	168	220%
EPS	3.3	10.6	220%
Reported EBITDA Margins	17.3%	25.1%	
Speciality Chemicals	26.8%	27.7%	
Nutrition & Health Solutions	21.0%	15.9%	
Life Science Chemicals	7.1%	27.3%	
Net Margin	7.1%	14.7%	

- Revenue grew by 55% on YoY basis, driven by robust growth in volume and prices.
- Speciality Chemicals revenue grew by 18% YoY driven by volume growth across product segments.
- Nutrition and Health Solutions revenue grew by 13% YoY driven by higher volumes and growth in Niacinamide price
- Life Sciences Chemical revenue grew by 103% YoY, driven by higher prices on account of favorable market conditions and pass-on of higher input cost of acetic acid
- EBITDA at Rs 287 Crore, grew by 126% on account of strong performance of Speciality Chemical & Life Sciences chemical segment led by favorable market conditions.
- PAT grew by 220% YoY driven by growth in EBITDA, added by reduction in finance cost by Rs 15 Crore through reduction in average debt by Rs 706 Crore and decrease in Interest rate by 0.75%, partially set off by higher tax expense.



- 1. All figures are in Rs Crore unless otherwise stated
- 2. Q1'FY21 is derived from 3 month of discontinued operation of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
 - EPS has been computed on combined profits assuming existence of share capital for full period.

Debt Profile – Q1 FY22




Particulars ¹	31/Mar/21	30/Jun/21
Long Term Borrowings	456	227
Short Term Borrowings	92	230
Total	548	457
Cash & Equivalent	117	70
Net Debt	431	386
QoQ change	-	-10%

- Gross Debt reduction of Rs 91 Crore in Q1'FY 22.
- Net Debt reduction of Rs 45 Crore in Q1'FY22.
- Net Debt to EBITDA in Q1'FY22 stands at 0.5 times, from the earlier lever of 0.7 times as on 31st March, 2021.
- Average blended interest rate for Q1'FY22 was 7.09%, against 7.84 % in Q1'FY21 and average debts during Q1'FY 22 was lower by Rs 706 Crore as compared to Q1' FY 21.


Jubilant Ingrevia Limited – FY21 Financial Highlights (Pro-forma²)

Particulars ¹	FY20	FY21	YoY (%)
Revenue			
Speciality Chemicals	1,104	1,124	2%
Nutrition & Health Solutions	537	630	17%
Life Science Chemicals	1,537	1,738	13%
Total Revenue from Operations	3,179	3,491	10%
Reported EBITDA	409	627	53%
Speciality Chemicals	237	268	13%
Nutrition & Health Solutions	95	130	37%
Life Science Chemicals	99	236	138%
Unallocated Corporate (Expenses)/Income	-22	-8	
РАТ	220	316	43%
EPS	13.8	19.9	43%
Reported EBITDA Margins	12.9%	17.9%	
Speciality Chemicals	21.4%	23.9%	
Nutrition & Health Solutions	17.7%	20.7%	
Life Science Chemicals	6.5%	13.6%	
Net Margin	6.9%	9.1%	





FY21 Industry End-Use Split




• Revenue grew by 10% on YoY basis, driven by growth in volume and pricing both.

UBILANI INGREVIA

- Speciality Chemicals revenue grew by 2% YoY driven growth in Fine Chemicals and new CDMO projects
- Nutrition and Health Solutions revenue grew by 17% YoY driven by conducive market condition and robust growth in Niacinamide prices
- Life Sciences Chemicals revenue grew by 13% YoY driven by favorable market conditions from Pharma, Packaging, Industrial applications both in domestic as well as export markets
- EBITDA at Rs 627 Crore, grew by 53% YoY
- PAT grew by 43% YoY driven by growth in EBITDA and reduction in finance cost through reduction in debt as well as interest rates
- PAT is after reduction of Exceptional items of Rs 13 Crore
- RoCE improved to 20.2% in FY21, from 12.0% in FY20, driven by increase in EBIT and optimization of working capital
- RoE stood at 16.4% in FY21
 - 1. All figures are in Rs Crore unless otherwise stated
 - 2. FY21 is calculated from 10 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited
 - FY20 is calculated from 12 month of discontinued operation of LSI segment of Jubilant Pharmova Limited
 - FY20 Segment EBITDA without Adjusting unallocated Corporate Expenses was Rs 431 Crore
 - EPS has been computed on combined profits assuming existence of share capital for full year.

Balance Sheet – Key Parameters/Ratios (Pro-Forma²)





- FY21 is calculated from 10 month of discontinued operation of LSI segment of Jub

- FY20 is calculated from LSI segment of Jubilant Pharmova Limited before unallocated expense/assets.

Our Vision, Values, Promise and Philosophy







Thank you

For More Information



For Investors:

Pavleen Taneja Ph: +91 120 436 1021 E-mail: pavleen.taneja@jubl.com

For Media:

Sudhakar Safaya Ph: +91 120 436 1034 E-mail: sudhakar.safaya@jubl.com Siddharth Rangnekar CDR India Ph: +91 22 6645 1209 E-mail: siddharth@cdr-india.com

Clayton Dsouza Madison Public Relations E-mail: clayton.dsouza@madisonpr.in Phone number: +91 9930011602

Thank you for your time

Jubilant Ingrevia Limited

1A, Sector-16A, Noida - 201 301, Uttar Pradesh, India Email: support@jubl.com | www.jubilantingrevia.com



Appendix

Pro-Forma Income Statement Consolidated – FY21 (10 months discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months Jubilant Ingrevia Limited)



Particulars ¹	FY20	10M'FY21	2M'FY21 Feb'21 to Mar'21	FY21	YoY (%)
Revenue from operations					
a) Sales/Income from operations	3,134	2,786	679	3,465	11%
b) Other operating income	45	2,700	5	27	(41%)
Total revenue from operations	3,179	2,807	684	3,491	10%
Other income	10	12	3	15	48%
Total income	3,189	2,819	687	3,506	10%
Expenses	0,200				
a) Cost of materials consumed	1,681	1,324	363	1,688	(0%)
b) Purchases of stock-in-trade	122	83	16	99	18%
c) Changes in inventories of finished goods,					
stock-in-trade and work-in progress	-118	59	-10	49	(142%)
d) Employee benefits expense	284	250	49	299	(5%)
e) Other expenses:					0%
- Power and fuel expense	362	272	52	324	11%
- Others	448	324	96	420	6%
Total expenses	2,779	2,312	567	2,879	(4%)
EBIDTA	409	507	120	627	53%
Depreciation and amortization expense	122	103	22	125	(2%)
EBIT	287	404	98	502	75%
Finance costs	88	63	7	71	20%
Profit before exceptional items and tax (3-4)	199	341	90	431	116%
Exceptional items	2	-	13	13	(661%)
Profit before tax (5-6)	198	341	77	418	112%
Tax expense	-23	79	-23	56	
Net Profit for the period (7-8)	220	262	54	316	43%

1. All figures are in Rs Crore unless otherwise stated 2. FY20 Segment EBITDA without Adjusting unallocated Corporate Expenses was Rs 431 Crore